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The objective of this study was to prospectively measure peri-diagnostic and surgical time intervals for patients with suspected
colorectal, lung, or prostate cancer. Prospective eligible patients were referred to a regional hospital in Ottawa, Canada between
February 2004 and February 2005 for diagnostic assessment of presumptive colorectal, lung, or prostate cancer. Chart abstractions
were used to measure nine time intervals; the primary interval was the date of referral for diagnostic assessment to the date the
patient was informed of the diagnosis. Health-related quality-of-life (HRQL) was assessed 5 days following the patient being informed
of their diagnosis. The median (IQR) time for the primary interval was 71 (30–110), 37 (29–49), and 81 (56–100) days for
colorectal, lung, and prostate patients, respectively (Kruskal–Wallis P¼0.0001). This interval was significantly less for colorectal
patients diagnosed with cancer than for those without cancer (median difference¼59.0 days; Wilcoxon P¼0.003). No differences in
HRQL existed for patients with cancer and those without. Colorectal and prostate patients wait longer between referral for
suspected cancer and being informed of their diagnosis than current recommendations. The shorter diagnostic intervals for colorectal
patients with cancer suggest clinicians have an effective process for triaging patients referred for diagnostic assessment.
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Patients with suspected cancer experience many waits as they
progress through their diagnostic assessment and treatment. These
wait times are a lightning rod in discussions about public-funded
health care systems (Lewis et al, 2000; Sanmartin et al, 2000;
Oliver, 2001; Thomas and Burnet, 2001; Sibbald, 2005). National-
level organisations have affirmed their commitment to establishing
evidence-based benchmarks for medically acceptable wait times
(Canadian Society for Surgical Oncology, n.d.; Department of
Health, 2000b; Health Canada, 2004; Wait Time Alliance, 2005).
The majority of Canadian-based recommendations consider only a
small portion of a cancer patient’s experience, such as wait times
for radiation therapy (Alberta Waitlist Registry, n.d.; Quebec
Ministry of Health and Social Services, n.d.; Wait Time Alliance,
2005; Cancer Care Ontario, 2006) and systemic therapy (Cancer
Care Ontario, 2006). United Kingdom recommendations involve
primary treatment (Department of Health, 2000b) as well as the
2-week wait rule for referral of urgent suspected cancer cases
(Department of Health, 2000a).
Although treatment time intervals are important, for patients the
experience is one of a series of waits starting with the
peri-diagnostic period (Wait Time Alliance, 2005). Moreover, the
peri-diagnostic period may critically impact subsequent outcomes
(Richards et al, 1999). Research from the EUROCARE project
(Gatta et al, 2000; Berrino et al, 2007) suggests that the lower
5-year survival ratios for breast and colorectal cancer in the United
Kingdom compared to Northern and Central European countries
might be attributed to higher disease stage at diagnosis. These
findings point to the need for timely referral processes and early
diagnoses.
Most studies of wait times use administrative data (Mayo et al,
2001; Johnston et al, 2004; Rayson et al, 2004; Simunovic et al,
2005; Liberman et al, 2006), yet the ability to document many of
the peri-diagnostic time intervals from routinely collected data is
limited. Moreover, these studies usually study patients with a
cancer diagnosis (Mayo et al, 2001; Johnston et al, 2004; Rayson
et al, 2004; Liberman et al, 2006) and do not report wait times for
those who are found not to have cancer. Wait times during the
peri-diagnostic period are a time of considerable psychological
stress for all patients, even those who turn out not to have cancer
(Benedict et al, 1994; Gray, 1997). The primary objective of
this study was to measure prospectively peri-diagnostic and
surgical time intervals for patients with suspected colorectal,
lung, or prostate cancer. The secondary objective was to assess
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shealth-related quality of life (HRQL) 1 week following cancer being
confirmed or ruled out.
MATERIALS AND METHODS
We conducted a study of patients referred to The Ottawa Hospital
(TOH) in Ottawa, Ontario from February 2004 to February 2005
for diagnostic assessment of presumptive colorectal, lung, or
prostate cancer. TOH is a university-affiliated regional hospital
serving Eastern Ontario and offers the full range of health care
services from primary care to tertiary cancer care. In 2004, it had
951 beds and served as the referral centre for a population of 1.12
million people and a geographic area of approximately 17600km
2.
The only cancer centre in the region is at TOH. In addition to
referral for presumptive cancer, patients were eligible for the study
if they were 18 years of age or older, provided written informed
consent, were able to complete the baseline questionnaire in
English or French, had no previous diagnosis of cancer in the past
5 years (except in situ cervix or non-melanoma skin), and had not
been receiving ongoing care/surveillance from a cancer centre or
tertiary care physician. The study was approved by TOH Research
Ethics Board.
Potentially eligible patients were identified from clinic lists of
all participating consultants (21 of 24, 87.5% of potential
consultants). Consultants included gastroenterologists and general
surgeons for presumptive colorectal cancer; respirologists and
thoracic surgeons for presumptive lung cancer; and urologists for
presumptive prostate cancer. All prospective patients were
approached to participate in the study, either in person on the
day of their first diagnostic consultation or by telephone within
24h. Upon providing written informed consent, patients were
enrolled in the study and followed until their first oncology
consultation or 3 months, whichever came first. Following
enrolment, patients completed a baseline questionnaire to provide
identifying and demographic information.
Chart abstraction and patient-completed questionnaires
were used to collect the data. Two experienced clinical
research associates, skilled in chart abstraction, conducted the
chart review. The primary time interval, calculated in days, was (1)
the date the referral for diagnostic assessment was received by the
consultant (based on the date of fax, letter, or telephone call
received in the consultant’s office, referred to hereafter as ‘date of
referral’) to the date the patient was informed of the diagnosis.
Secondary time intervals, calculated in days, were (2) date of
referral to date of confirmed diagnosis (date of the pathology or
radiology report, or date of colonoscopy for colorectal patients
informed of malignancy or non-malignancy immediately after
colonoscopy); (3) date of referral to date of first diagnostic
consultation (or date of first relevant investigation initiated by
consultant, whichever came first; relevant investigations included
biopsy, bronchoscopy, chest X-ray, colonoscopy, sigmoidoscopy,
CT scan, MRI, PSA, pulmonary function test, transrectal ultra-
sound, and other); (4) date of first diagnostic consultation to date
patient informed of diagnosis; (5) date of confirmed diagnosis to
date of surgery or decision for no surgery (date of decision for no
surgery based on consultant notes); (6) date of referral to date of
surgery or decision for no surgery; (7) date of referral to date of
surgery; (8) date of surgery to date of first oncology consultation
or decision for no consultation (date of decision for no
consultation based on consultant notes); and (9) date of referral
to date of initiation of first treatment (first treatment was defined
as neoadjuvant chemotherapy, surgery if no preoperative
treatment was required, chemotherapy, radiotherapy, or a decision
for no treatment). See Figure 1 for a schematic of the
time intervals. Patient comorbidity at the time of diagnostic
assessment was calculated using the Charlson comorbidity index
(Charlson et al, 1987).
Patients completed study questionnaires 5 days after the date
they were informed of their diagnosis (either confirming or ruling
out cancer), consisting of the following instruments: European
Organization of Research and Treatment of Cancer quality of life
core questionnaire (EORTC QLQ-C30) HRQL (30 items; range:
0–100; higher scores reflect better quality of life; Aaronson, 1995);
the Hospital Anxiety and Depression Scale (HADS) to measure
anxiety and depression (14 items; range: 0–21; higher scores
reflect higher levels of anxiety or depression) (Zigmond and
Snaith, 1983); and the SF-36 to measure physical and mental
functioning (36 items; range: 0–100; higher scores reflect better
functioning; Brazier et al, 1992). The questionnaires were mailed to
patients with instructions to complete and return immediately.
Received questionnaires were reviewed for completeness and
patients were seen in clinic or contacted by telephone to complete
missing items. If the questionnaires were not received within 3
working days, patients were seen in clinic or contacted by
telephone and the questionnaire was completed at that time.
Descriptive statistics and associated analyses were performed in
SAS for Windows version 9.1. Descriptive data are presented both
as means and standard deviations and medians and interquartile
ranges to facilitate a better description of the wait times and to
enable the data to be used in future economic and other analyses.
Simple logistic regression was used to compute odds ratios and
95% confidence intervals by suspected disease site for diagnosis of
cancer and the attributes comorbidity, sex, and referring physician
(family physician or specialist (gastroenterologists, respirologists,
urologists, and surgeons)). Analyses of variance (ANOVA) were
used to compare differences between disease sites for the primary
time interval; t-tests were used to compare differences between
patients with and without cancer for this same interval. Concerns
about the skewness or other non-normality of continuous
outcomes were addressed by sensitivity analysis using non-
parametric procedures, in particular the Kruskal–Wallis rank
sum test as a check on ANOVAs and the Wilcoxon rank sum test
as a check on t-tests. The data were not log-transformed due to the
objective of measuring and describing time intervals, and hence
the need to maximise interpretability. For the primary time
interval, parameter estimates were also computed via a multi-
variable linear regression model, with age, sex, comorbidity, and
referring physician as the covariables. Although the data are
descriptive, we followed the convention of noting statistical
significance when the two-sided P value was less than 0.05. For
comparative purposes, data are primarily reported as medians and
interquartile ranges. However, as noted above, ANOVAs and
t-tests using means and variances were used to compare
differences for the primary time interval. Accordingly, P values
should be interpreted with caution. For the questionnaire data,
t-tests were used to compare differences between patients with and
without cancer, whereas ANOVAs were used to compare
differences between disease sites. A two-sided P value o0.05 was
used to determine statistical significance.
RESULTS
During the study period, 461 patients met the eligibility criteria
and 369 agreed to participate. Of these patients, 350 patients
completed the questionnaires and represent the study population
(76% participation rate). Patient characteristics are presented in
Table 1. Lung patients were more likely to have comorbidities
(lung vs colorectal: OR¼2.63, 95% CI¼1.52–4.55; lung vs
prostate: OR¼2.17, 95% CI¼1.23–3.82) and were more likely to
have been referred by someone other than a family physician (lung
vs colorectal: OR¼2.49, 95% CI¼1.27–4.88; lung vs prostate:
OR¼2.86, 95% CI¼1.39–5.92) than either colorectal or prostate
patients. The two most common reasons for referral for each type
of cancer were: change in bowel habit plus age 450 years (n¼53)
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sand rectal bleeding with a change in bowel habit (n¼34) for
suspected colorectal cancer; suspicious lung nodule(s) or lesion or
mass on diagnostic imaging (n¼98) and smoker plus suspicious
symptoms (n¼47) for suspected lung cancer; and increased PSA
(n¼102) and abnormal digital rectal exam (n¼18) for suspected
prostate cancer.
Lung patients were more likely to be diagnosed with cancer
(80.2%) than either colorectal (6.8%) or prostate patients (35.3%;
colorectal vs lung: 95% CI¼0.008–0.04; lung vs prostate: 95%
CI¼3.93–13.60). Descriptive statistics for all time intervals are
presented in Table 2. The primary outcome of this study was the
time interval from the date of referral to the date the patient was
Interval 9
Interval 4 Interval 3
Interval 2
Interval 1
Interval 5
Interval 8 Intervals 6 and 7
Referral Consultation Confirmed
diagnosis
Patient informed
of diagnosis
Surgery /
decision for No
surgery
Oncology
consultation /
decision for no
consultation
Initiation of the
first treatment /
decision for no
treatment
Primary Time Interval
Secondary Time Interval
1. Date the referral for diagnostic assessment was received by the consultant (‘date of referral’) to date patient informed of diagnosis.
2. Date of referral to date of confirmed diagnosis.
6. Date of referral to date of surgery or decision for no surgery.
7. Date of referral to date of surgery.
8. Date of surgery to date of first oncology consultation or decision for no consultation.
9. Date of referral to date of initation of first treatment (first treatment was defined as neoadjuvant chemotherapy, surgery if no preoperative
    treatment was required, chemotherapy, radiotherapy, or a decision for no treatment); dotted lines reflect possible interval endpoints.
3. Date of referral to date of first diagnostic consultation.
4. Date of first diagnostic consultation to date patient informed of diagnosis.
5. Date of confirmed diagnosis to date of surgery or decision for no surgery.
Figure 1 Peri-diagnostic and treatment time intervals.
Table 1 Participant characteristics (n¼350)
Colorectal Lung Prostate
All
a Cancer
b No cancer
c All
a Cancer
b No cancer
c All
a Cancer
b No cancer
c
Number (%) 133 9 (6.8) 124 (93.2) 101 81 (80.2) 20 (19.8) 116 41 (35.3) 75 (64.7)
Age; mean (s.d.) 62.3 (11.2) 73.8 (8.8) 61.4 (11.0) 65.0 (11.8) 66.4 (11.6) 59.5 (11.1) 65.5 (9.4) 65.6 (9.8) 65.5 (9.2)
Sex (no.)
Male 71 7 64 58 48 10 116 41 75
Female 62 2 60 43 33 10 — — —
Marital status (no.)
Single 8 0 8 6 4 2 8 1 7
Married 103 7 96 63 52 11 91 34 57
Divorced 13 0 13 13 10 3 14 5 9
Widowed 9 2 7 19 15 4 3 1 2
Comorbidity (no.)
d
0 1 0 1 4 9 75 5 4 11 48 4 3 1 5 3
1 22 3 19 22 21 1 23 5 18
2 7 1 6 11 8 3 6 4 2
43 3 1 2 13 11 2 3 1 2
Referring physician (no.)
Family physician 116 9 107 74 63 11 103 38 65
Surgeon 4 0 4 3 2 1 1 0 1
Specialist
e 1 0 15 234 2 2
Other 12 0 12 19 14 5 8 1 7
aAll patients referred with symptoms suggestive of cancer.
bPatients for whom cancer was confirmed.
cPatients for whom cancer was confuted.
dCharlson comorbidity scores:
range from 0 to 10 with a higher score indicating greater number of comorbid conditions (Charlson et al, 1987).
eSpecialists included gastroenterologists, respirologists, and
urologists.
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sinformed of the diagnosis. This interval varied significantly
between cancer sites: lung patients had significantly shorter time
intervals (median 37 (IQR 29–49) days) than colorectal (median
71 (IQR 30–110) days) or prostate patients (median 81 (IQR 56–
100) days, Kruskal–Wallis P¼0.0001). On multivariable linear
regression analysis, the level of comorbidity for lung patients was
the only factor associated with differences in the interval from referral
to patient informed of diagnosis (estimated coefficient¼14.31;
P¼0.04). Age, sex, and referring physician were not associated
with differences in this time interval.
Colorectal patients with cancer had significantly shorter time
intervals between referral and being informed of diagnosis than
colorectal patients without cancer (mean 33.8 (s.d. 48.9) days and
mean 84.8 (s.d. 67.7) days, respectively, Wilcoxon P¼0.003; see
Table 3). There was no difference in this time interval for patients
with and without suspected lung or prostate cancer.
Table 4 presents the questionnaire scores 1 week after diagnosis
for patients with and without cancer. No differences in health
status or HRQL existed between those patients diagnosed with
cancer and those found not to have cancer.
DISCUSSION
Most studies of cancer diagnostic time intervals are retrospective
in design, using administrative data of patients with cancer. This
study is unique in prospectively measuring intervals for patients
with presumptive cancer, several of which cannot be captured
from routinely collected administrative data. Although it is
possible to derive many time intervals from administrative data
and such data permit researchers to conduct population-based
studies, the gold standard is prospectively collected data from
patient records. That is, the outcome of interest (eg, time intervals)
is unknown at the outset of the study and measured over time,
whereas the patient chart provides data that are not attainable
from administrative data. The value of our approach, from a
patient-centred perspective, is best illustrated by the two different
definitions of the interval ‘from referral to diagnosis’: the ‘date of
diagnosis’ in the first definition is the date the patient is informed,
and in the second definition it is the date of the confirmatory
report from pathology, radiology, or procedure (eg, colonoscopy).
Considering the median for patients with cancer as an example, the
Table 2 Time intervals to diagnosis, surgery, and oncology consultation (n¼350)
Colorectal Lung Prostate
Time interval
(days)
All
a
(n¼133)
Cancer
b
(n¼9)
No cancer
c
(n¼124)
All
a
(n¼101)
Cancer
b
(n¼81)
No cancer
c
(n¼20)
All
a
(n¼116)
Cancer
b
(n¼41)
No cancer
c
(n¼75)
1. Referral to patient informed of diagnosis
Mean (s.d.) 81.3 (67.7) 33.8 (48.9) 84.8 (67.7) 45.2 (32.4) 43.5 (31.7) 52.2 (35.1) 82.3 (42.9) 91.3 (37.4) 77.5 (45.1)
Median (IQR) 71 (30–110) 13 (8–35) 72 (32–111) 37 (29–49) 35 (28–49) 42 (36–49) 81 (56–100) 85 (73–100) 77 (40–100)
2. Referral to confirmed diagnosis
d
Mean (s.d.) 75.2 (63.6) 31.0 (45.2) 78.4 (63.7) 35.5 (31.5) 33.6 (31.1) 43.1 (32.6) 68.0 (38.3) 72.6 (35.0) 65.4 (40.0)
Median (IQR) 66 (29–103) 13 (8–32) 71 (30–104) 28 (21–37) 28 (19–35) 33 (26–45) 65.5 (44–84) 66 (58–80) 64 (37–84)
3. Referral to first diagnostic consult
e
Mean (s.d.) 55.1 (48.4) 13.4 (11.6) 58.2 (48.7) 13.9 (11.4) 12.6 (9.9) 19.2 (15.1) 38.0 (24.6) 40.4 (28.0) 36.7 (22.6)
Median (IQR) 43 (17–79) 9 (7–13) 48 (20–81) 12 (6–19) 11 (6–18) 14 (10–26) 35 (25–49) 35 (29–50) 34 (24–49)
4. First diagnostic consult to patient informed of diagnosis
Mean (s.d.) 26.6 (42.3) 20.3 (51.9) 27.0 (41.7) 31.4 (32.3) 31.0 (32.6) 33.1 (31.7) 44.3 (31.7) 50.9 (22.1) 40.8 (35.5)
Median (IQR) 0 (0–40) 0 (0–11) 1.5 (0–44) 25 (14–35) 25 (13–37) 24 (19–35) 45 (28–58) 47 (37–58) 39 (0–58)
5. Confirmed diagnosis to surgery/
decision for no surgery
n¼9n ¼73 n¼41
Mean (s.d.) — 33.9 (23.3) — — 22.7 (18.8) — — 61.6 (45.7) —
Median (IQR) — 23 (17–43) — — 16 (10–28) — — 54 (19–96) —
6. Referral to surgery/decision for no
surgery
n¼9n ¼77 n¼41
Mean (s.d.) — 64.9 (42.0) — — 54.9 (39.2) — — 134.2 (62.2) —
Median (IQR) — 64 (30–76) — — 45 (35–63) — — 128 (80–168) —
7. Referral to surgery
f n¼8n ¼23 n¼20
Mean (s.d.) — 53.1 (24.3) — — 72.9 (51.3) — — 170.2 (59.9) —
Median (IQR) — 54.5 (30–76) — — 57 (44–91) — — 162 (120–215) —
8. Surgery to oncology consult/
decision for no consult
n¼3n ¼20 n¼6
Mean (s.d.) — 21.0 (18.2) — — 39.7 (33.9) — — 18.7 (21.8) —
Median (IQR) — 11 (10–42) — — 35 (22–47) — — 10.5 (8–12) —
9. Referral to initiation of first
treatment
g
n¼9n ¼81 n¼41
Mean (s.d.) — 64.0 (41.8) — — 55.5 (38.9) — — 113.6 (52.4) —
Median (IQR) — 64 (30–75) — — 45 (35–64) — — 94 (79–135) —
aAll patients referred with symptoms suggestive of cancer.
bPatients for whom cancer was confirmed.
cPatients for whom cancer was confuted.
dDate of pathology, radiology, or
procedural report confirming cancer diagnosis.
eDate of first diagnostic consult was defined as the date first seen by a consultant or the date of the first relevant investigation
initiated by consultant, whichever came first.
fIncludes only those patients who underwent surgery.
gFirst treatment was defined as neoadjuvant chemotherapy, surgery if no
preoperative treatment was required, chemotherapy, radiotherapy, or a decision for no treatment.
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sdifference between the first and second definitions was 0 days for
colorectal cancer, 7 days for lung cancer, and 19 days for prostate
cancer. Therefore, for the patient, the wait for their diagnosis can
be 2.5 weeks longer than the confirmatory date, but it is only the
latter date that is available from administrative data. Although
there are very good reasons to use the second ‘confirmatory’
definition, including its practicality when using routinely collected
data, the first definition highlights the fact that the patient may
experience significantly longer waits than the administrative data
reveal.
In Canada, research on wait times often comprises the surgical
and treatment periods (Johnston et al, 2004; Simunovic et al,
2005), whereas most reports of diagnostic time intervals for
patients with presumptive cancer involve breast cancer (Mayo
et al, 2001; Olivotto et al, 2001; Rayson et al, 2004). In the United
Kingdom, however, the introduction of the 2-week rule for urgent
referrals has generated much research into referral for presump-
tive cancer, with results indicating that the majority of patients
urgently referred with symptoms suggestive of cancer are seen by a
consultant within 14 days of referral (Debnath et al, 2002; Scott
et al, 2006). Although studies also report time intervals following
referral (Allgar and Neal, 2005; Neal et al, 2007), variations across
studies in the precise definitions of the time intervals as well as the
data capture methods make direct comparisons difficult. Standard-
ising wait time terminology will permit improved comparison over
time and across jurisdictions. We present our results here as
medians as well as means and standard deviations to allow for the
greatest flexibility in any future comparisons.
The time interval between the date of referral and confirmed
diagnosis was much shorter for patients with presumptive lung
cancer than for patients with presumptive colorectal or prostate
cancer. The longer intervals for colorectal and prostate patients
may reflect the subtle and non-specific nature of symptoms
(Roncoroni et al, 1999; Allgar and Neal, 2005). Conversely, signs
and symptoms leading to referral for investigation of possible lung
cancer are strongly predictive and there is a readily available
diagnostic test (e.g., chest X-ray). Indeed, lung patients in our
study were most likely to have cancer, with the most common
referral reason being suspicious lung nodule(s) or lesion or mass
on diagnostic imaging. Nonetheless, differences in the presentation
of signs/symptoms and diagnostic processes associated with
different cancers underlines the value of the present data for
informing policies and standards on diagnostic intervals, and
supports the need for a more nuanced approach when setting wait
time standards.
Patients with presumptive colorectal cancer show an interesting
pattern. Those with cancer both saw the consultant and were
informed of their diagnosis sooner than those without cancer
(median 9 days vs 48 days; median 13 days vs 72 days,
respectively), suggesting that clinicians have an effective process
for triaging patients referred for diagnostic assessment. Similar
effects have been reported for Canadian breast patients (Olivotto
et al, 2001). Surprisingly, this triaging is not necessarily apparent
in data gathered because the implementation of the United
Kingdom’s urgent 2-week rule, which was intended to facilitate
the triage system. For example, though the majority of suspected
colorectal cancer patients may see a consultant within the 2-week
period (Debnath et al, 2002; Scott et al, 2006; Neal et al, 2007),
those patients can wait considerably longer for their diagnosis
once entering the hospital system (Neal et al, 2007).
The time intervals between referral and confirmed diagnosis for
all patients were longer than the Canadian Strategy for Cancer
Control’s (CSCC) recommended 4-week maximum between the
first visit to a physician and diagnosis (2002). In fact, colorectal
and prostate patients waited longer than 10 weeks between referral
for suspected cancer and being informed of their diagnosis.
The Canadian Society for Surgical Oncology (n.d.) recommends
that the time from referral to first consultation should not exceed
2 weeks; this recommendation is consistent with the United
Kingdom 2-week rule for urgent suspected cancers (Department of
Health, 2000a). Only lung patients in our study came close to
meeting these recommendations.
The prolonged peri-diagnostic waits experienced by our color-
ectal and prostate patients, as well as the lengthy wait times
reported by others (Spurgeon et al, 2000; Porter et al, 2005), point
towards the need to further understand the nature and dynamics of
cancer referrals and diagnoses. Canada, Australia, the United
Kingdom, and many European countries employ a ‘gatekeeping’
model of health care (Ge ´rvas et al, 1994; Brennan and Houssami,
2006), whereby primary care providers act as the point of entry
each time care is sought for a health problem. The best way to use
this model to serve patients requiring prompt specialist care is an
issue requiring further investigation. The CSCC (2006), Australia’s
National Service Improvement Framework for Cancer (National
Health Priority Action Council, 2006), and the United Kingdom’s
new Cancer Reform Strategy (Department of Health, 2007) all
emphasise the importance of earlier diagnoses for improved
cancer control, including the need to further study wait times in
cancer diagnosis to strengthen the primary care provider’s ability
to facilitate early diagnosis.
We found no differences in HRQL and health status between
patients with cancer and those without. This may reflect the
unexplained signs and symptoms and continued uncertainty that
those without cancer presumably still had, despite non-malignant
findings. Others have found that subjective measures of care
(eg, satisfaction) are more sensitive to changes in the interval from
diagnosis to surgery than to changes in the peri-diagnostic period
(Porter et al, 2005). Perhaps patients’ HRQL and anxiety also
escalate in the time between diagnosis and subsequent treatment
events, whereas our assessment largely represents the peri-
diagnostic period.
Although we measured wait time intervals in the peri-diagnostic
period, we do not provide any information on patient factors
contributing to these intervals. Another limitation of this study is
that the impact of wait times on outcomes was not determined.
This is recognised as an important missing element in our
knowledge about wait times (CSCC, 2002). As our objective was to
describe wait time intervals for patients with suspected cancer, we
did not obtain additional clinical and pathological data on the
tumours nor did we follow patients after treatment to measure
outcomes. Finally, our study examined time intervals at one
regional hospital in Ontario, which may not be representative of
Table 3 Time interval from date of referral to date patient informed of diagnosis: comparison of patients with and without cancer
Cancer
a No cancer
b
days; mean (s.d.) Difference (95% CI) t-test P-value Wilcoxon P-value
Colorectal (n¼133) 33.8 (48.9) 84.8 (67.7) 51 (5.4–96.6) 0.03 0.003
Lung (n¼101) 43.5 (31.7) 52.2 (35.1) 8.7 ( 7.3–24.7) 0.28 0.14
Prostate (n¼116) 91.3 (37.4) 77.5 (45.0)  13.8 ( 30.2–2.6) 0.10 0.09
All (n¼350) 57.8 (41.4) 79.3 (58.9) 21.5 (10.0–33.0) 0.0001 0.0007
aPatients for whom cancer was confirmed.
bPatients for whom cancer was confuted.
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swait times throughout Canada or indeed other primary care-based
health care systems.
Despite the heightened political interest in timely access to health
care, acceptable and effective wait time benchmarks for the peri-
diagnostic period have not been established. To our knowledge, this
study is the first to measure prospectively diagnostic wait time intervals
for suspected colorectal, lung, and prostate cancers in Canada. As such,
it provides important descriptive data to assess and determine
benchmark measures. Furthering the work of wait time initiatives
(Wait Time Alliance, 2005) is vital to ensure common definitions are
Table 4 Comparison of health status and quality of life 1 week after diagnosis for patients with and without cancer
Parameter; mean (s.d.) All
a Cancer
b No cancer
c Difference (95% CI) P-value
SF36 PCS
Colorectal 46.29 (10.66) 41.54 (7.52) 46.58 (10.78) 5.04 ( 3.84–13.92) 0.26
Lung 37.81 (11.75) 36.94 (11.64) 41.37 (11.88) 4.43 ( 2.06–10.93) 0.18
Prostate 50.27 (10.01) 52.04 (11.04) 49.23 (9.28)  2.81 ( 6.80–1.18) 0.16
P-value (difference between disease sites) ANOVA¼0.0001 kw¼0.0001
SF36 MCS
Colorectal 48.75 (10.40) 49.28 (8.79) 48.71 (10.53)  0.57 ( 9.29–8.15) 0.90
Lung 42.71 (15.14) 42.54 (14.34) 43.40 (18.59) 0.86 ( 7.61–9.32) 0.84
Prostate 52.57 (9.08) 50.49 (10.11) 53.80 (8.25) 3.31 ( 0.29–6.90) 0.07
P-value (difference between disease sites) ANOVA¼0.0001 kw¼0.0001
HADS Anxiety
Colorectal 3.37 (1.09) 3.17 (0.98) 3.38 (1.09) 0.22 ( 0.69–1.13) 0.63
Lung 3.63 (1.18) 3.63 (1.18) 3.63 (1.20) 0.00 ( 0.66–0.65) 0.99
Prostate 2.87 (0.88) 2.87 (0.92) 2.87 (0.87) 0.02 ( 0.33–0.38) 0.90
P-value (difference between disease sites) ANOVA¼0.0001 kw¼0.0001
HADS Depression
Colorectal 5.70 (2.1) 4.83 (0.98) 5.75 (2.15) 0.92 ( 0.83–2.68) 0.30
Lung 6.93 (2.84) 7.13 (2.84) 6.12 (2.75)  1.01 ( 2.58–0.56) 0.20
Prostate 5.06 (1.57) 4.97 (1.77) 5.10 (1.46) 0.16 ( 0.48–0.79) 0.62
P-value (difference between disease sites) ANOVA¼0.0822 kw¼0.0825
EORTC QLQ C-30
Physical functioning
Colorectal 85.52 (18.55) 73.33 (19.78) 86.26 (18.31) 12.93 ( 2.40–28.26) 0.10
Lung 65.27 (27.34) 63.79 (27.59) 71.25 (26.30) 7.46 ( 7.74–22.65) 0.33
Prostate 91.74 (14.96) 91.97 (17.52) 91.34 (13.68)  0.63 ( 6.69–5.45) 0.84
P-value (difference between disease sites) ANOVA¼0.0001 kw¼0.0001
Role functioning
Colorectal 82.06 (23.54) 72.22 (27.22) 82.66 (23.32) 10.44 ( 9.18–30.05) 0.29
Lung 53.09 (39.89) 53.59 (39.80) 51.04 (41.49)  2.55 ( 24.84–19.74) 0.82
Prostate 90.98 (19.45) 88.46 (22.99) 92.04 (17.49) 3.58 ( 4.28–11.44) 0.37
P-value (difference between disease sites) ANOVA¼0.0001 kw¼0.0001
Emotional functioning
Colorectal 77.78 (19.70) 76.39 (12.27) 77.86 (20.10) 1.47 ( 15.03–17.98) 0.86
Lung 67.59 (26.48) 67.82 (25.43) 66.67 (31.33)  1.15 ( 15.96–13.65) 0.88
Prostate 82.72 (18.38) 79.27 (18.82) 84.20 (18.24) 4.93 ( 2.44–12.30) 0.19
P-value (difference between disease sites) ANOVA¼0.0001 kw¼0.0001
Cognitive functioning
Colorectal 85.71 (17.52) 91.67 (13.94) 85.35 (17.70)  6.31 ( 20.94–8.31) 0.39
Lung 72.84 (25.34) 71.79 (26.34) 77.08 (20.97) 5.29 ( 8.83–19.40) 0.46
Prostate 88.07 (16.99) 85.47 (19.93) 89.30 (15.27) 3.83 ( 3.01–10.67) 0.27
P-value (difference between disease sites) ANOVA¼0.0001 kw¼0.0001
Social functioning
Colorectal 83.97 (22.51) 75.00 (22.97) 84.52 (22.58) 9.52 ( 9.25–28.30) 0.32
Lung 63.37 (34.00) 63.33 (34.38) 63.54 (33.45) 0.21 ( 18.79–19.21) 0.98
Prostate 91.74 (14.81) 89.32 (17.31) 92.79 (13.37) 3.47 ( 2.49–9.43) 0.25
P-value (difference between disease sites) ANOVA¼0.0001 kw¼0.0001
Global Health Status
Colorectal 69.47 (18.64) 59.72 (17.81) 70.07 (18.61) 10.35 ( 5.15–25.84) 0.19
Lung 51.34 (25.53) 50.51 (25.25) 54.69 (27.21) 4.18 ( 10.07–18.42) 0.56
Prostate 76.99 (16.59) 75.00 (20.23) 77.61 (14.23) 2.61 ( 4.05–9.27) 0.48
P-value (difference between disease sites) ANOVA¼0.0001 kw¼0.0001
PCS¼physical component summary of Short-Form 36; kw¼Kruskal–Wallis rank sum test; MCS¼mental component summary of Short-Form 36; ANOVA¼analyses of
variance; EORTC QLQ C-30¼European Organization of Research and Treatment of Cancer quality of life core questionnaire; HADS¼hospital anxiety and depression scale.
aAll patients referred with symptoms suggestive of cancer.
bPatients for whom cancer was confirmed.
cPatients for whom cancer was confuted.
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sestablished to aid in the measurement and comparison of wait times, to
manage wait times more effectively, and to monitor changes over time.
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